Tuo Song, Xiaozhen Diao, Jun Cheng, Yang Man, Boyu Chen, Haixing Zhang, Wenhui Wu
{"title":"在大肠杆菌中表达沙蚕(Perinereis aibuhitensis)的重组凝血酶原激活剂。","authors":"Tuo Song, Xiaozhen Diao, Jun Cheng, Yang Man, Boyu Chen, Haixing Zhang, Wenhui Wu","doi":"10.3390/bioengineering11101030","DOIUrl":null,"url":null,"abstract":"<p><p>As an essential thrombolytic agent, the tissue plasminogen activator receives increasing attention due to its longer half-life, lower immunogenicity, and easier administration, which are superior to other thrombolytic agents. In this study, the isolated and purified plasminogen activator from the sandworm (<i>Perinereis aibuhitensis</i>) was expressed in <i>E</i>. <i>coli</i> (<i>Escherichia coli</i>) to investigate its potential for simplifying the development process. The sandworm plasminogen activator was previously successfully cloned and expressed in <i>E</i>. <i>coli</i> with low yield and activity in the culture supernatant. This low yield and activity prompted us to optimize its DNA sequence. Furthermore, to raise the efficiency in the separation of the target protein, the protein's solubility was enhanced by fusing it with maltose-binding protein (MBP) tags. Eventually, the fibrinolytic activity was successfully restored after digestion with tobacco etch virus (TEV) protease. This study provides an innovative method of efficiently expressing and purifying plasminogen activators from sandworm in <i>E</i>. <i>coli</i> and broadens its applications in therapeutic treatment of cardiovascular diseases, including thrombosis, stroke, and coronary atherosclerotic heart disease.</p>","PeriodicalId":8874,"journal":{"name":"Bioengineering","volume":"11 10","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504054/pdf/","citationCount":"0","resultStr":"{\"title\":\"Recombinant Plasminogen Activator of the Sandworm (<i>Perinereis aibuhitensis</i>) Expression in <i>Escherichia coli</i>.\",\"authors\":\"Tuo Song, Xiaozhen Diao, Jun Cheng, Yang Man, Boyu Chen, Haixing Zhang, Wenhui Wu\",\"doi\":\"10.3390/bioengineering11101030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>As an essential thrombolytic agent, the tissue plasminogen activator receives increasing attention due to its longer half-life, lower immunogenicity, and easier administration, which are superior to other thrombolytic agents. In this study, the isolated and purified plasminogen activator from the sandworm (<i>Perinereis aibuhitensis</i>) was expressed in <i>E</i>. <i>coli</i> (<i>Escherichia coli</i>) to investigate its potential for simplifying the development process. The sandworm plasminogen activator was previously successfully cloned and expressed in <i>E</i>. <i>coli</i> with low yield and activity in the culture supernatant. This low yield and activity prompted us to optimize its DNA sequence. Furthermore, to raise the efficiency in the separation of the target protein, the protein's solubility was enhanced by fusing it with maltose-binding protein (MBP) tags. Eventually, the fibrinolytic activity was successfully restored after digestion with tobacco etch virus (TEV) protease. This study provides an innovative method of efficiently expressing and purifying plasminogen activators from sandworm in <i>E</i>. <i>coli</i> and broadens its applications in therapeutic treatment of cardiovascular diseases, including thrombosis, stroke, and coronary atherosclerotic heart disease.</p>\",\"PeriodicalId\":8874,\"journal\":{\"name\":\"Bioengineering\",\"volume\":\"11 10\",\"pages\":\"\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11504054/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioengineering\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.3390/bioengineering11101030\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/bioengineering11101030","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
摘要
作为一种重要的溶栓药物,组织纤溶酶原激活剂因其半衰期较长、免疫原性较低、给药方便等优于其他溶栓药物的特点而受到越来越多的关注。本研究在大肠杆菌(Escherichia coli)中表达了从沙蚕(Perinereis aibuhitensis)中分离纯化的纤溶酶原激活剂,以研究其简化开发过程的潜力。沙蚕纤溶酶原激活剂以前曾在大肠杆菌中成功克隆和表达,但产量和培养上清中的活性都很低。这种低产量和低活性促使我们对其 DNA 序列进行优化。此外,为了提高目标蛋白的分离效率,我们还通过融合麦芽糖结合蛋白(MBP)标签来增强蛋白的可溶性。最后,经烟草蚀刻病毒(TEV)蛋白酶消化后,成功恢复了纤溶活性。这项研究提供了一种在大肠杆菌中高效表达和纯化沙蚕纤溶酶原激活剂的创新方法,拓宽了其在血栓形成、中风和冠状动脉粥样硬化性心脏病等心血管疾病治疗中的应用。
Recombinant Plasminogen Activator of the Sandworm (Perinereis aibuhitensis) Expression in Escherichia coli.
As an essential thrombolytic agent, the tissue plasminogen activator receives increasing attention due to its longer half-life, lower immunogenicity, and easier administration, which are superior to other thrombolytic agents. In this study, the isolated and purified plasminogen activator from the sandworm (Perinereis aibuhitensis) was expressed in E. coli (Escherichia coli) to investigate its potential for simplifying the development process. The sandworm plasminogen activator was previously successfully cloned and expressed in E. coli with low yield and activity in the culture supernatant. This low yield and activity prompted us to optimize its DNA sequence. Furthermore, to raise the efficiency in the separation of the target protein, the protein's solubility was enhanced by fusing it with maltose-binding protein (MBP) tags. Eventually, the fibrinolytic activity was successfully restored after digestion with tobacco etch virus (TEV) protease. This study provides an innovative method of efficiently expressing and purifying plasminogen activators from sandworm in E. coli and broadens its applications in therapeutic treatment of cardiovascular diseases, including thrombosis, stroke, and coronary atherosclerotic heart disease.
期刊介绍:
Aims
Bioengineering (ISSN 2306-5354) provides an advanced forum for the science and technology of bioengineering. It publishes original research papers, comprehensive reviews, communications and case reports. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. All aspects of bioengineering are welcomed from theoretical concepts to education and applications. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. There are, in addition, four key features of this Journal:
● We are introducing a new concept in scientific and technical publications “The Translational Case Report in Bioengineering”. It is a descriptive explanatory analysis of a transformative or translational event. Understanding that the goal of bioengineering scholarship is to advance towards a transformative or clinical solution to an identified transformative/clinical need, the translational case report is used to explore causation in order to find underlying principles that may guide other similar transformative/translational undertakings.
● Manuscripts regarding research proposals and research ideas will be particularly welcomed.
● Electronic files and software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.
● We also accept manuscripts communicating to a broader audience with regard to research projects financed with public funds.
Scope
● Bionics and biological cybernetics: implantology; bio–abio interfaces
● Bioelectronics: wearable electronics; implantable electronics; “more than Moore” electronics; bioelectronics devices
● Bioprocess and biosystems engineering and applications: bioprocess design; biocatalysis; bioseparation and bioreactors; bioinformatics; bioenergy; etc.
● Biomolecular, cellular and tissue engineering and applications: tissue engineering; chromosome engineering; embryo engineering; cellular, molecular and synthetic biology; metabolic engineering; bio-nanotechnology; micro/nano technologies; genetic engineering; transgenic technology
● Biomedical engineering and applications: biomechatronics; biomedical electronics; biomechanics; biomaterials; biomimetics; biomedical diagnostics; biomedical therapy; biomedical devices; sensors and circuits; biomedical imaging and medical information systems; implants and regenerative medicine; neurotechnology; clinical engineering; rehabilitation engineering
● Biochemical engineering and applications: metabolic pathway engineering; modeling and simulation
● Translational bioengineering